Amgen Inc

AMGN · Biotechnology · $208.5B
Cooling off
AMGN
$385.65
▲ +1.55%
09/18 O 378.51 H 386.50 L 378.51 C 385.65 ▲ +1.55%
Vol 8.5M RS 71
RS rating71
Now vs pivot (%)−1.44%
Tightening (ATR ratio)0.97×
Volume dry-up1.00×
Up/down volume, net0.11
From 52-week high14%
failed pokeplayed out
Previous breakout trailed out ▲ +1.27% in Jan
Cooling off
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 20.4 weeks and fell 18% from its ceiling at its deepest. The pivot is $391.29, and the stock closed 1.4% below it. Its relative strength rating is 71.

Peers
Catalyst roadmap
  1. EarningstentativeLLY · industryin 41d
    LLY reports
    Oct 29, 2026
  2. EarningstentativeAAPL · industryin 41d
    AAPL reports
    Oct 29, 2026
  3. Earningstentativein 46d
    Quarterly earnings
    Nov 3, 2026
Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Amgen Inc (AMGN) — The Tape